MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa2400985

Медицинская библиотека · The New England journal of medicine · 2024

Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors.

Plotkin Scott R, Yohay Kaleb H, Nghiemphu Phioanh L, Dinh Christine T, Babovic-Vuksanovic Dusica, Merker Vanessa L, Bakker Annette, Fell Geoffrey, Trippa Lorenzo, Blakeley Jaishri O, INTUITT-NF2 Consortium

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеAdaptive Clinical TrialПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

BACKGROUND

NF2-related schwannomatosis (NF2-SWN, formerly called neurofibromatosis type 2) is a tumor predisposition syndrome that is manifested by multiple vestibular schwannomas, nonvestibular schwannomas, meningiomas, and ependymomas. The condition is relentlessly progressive with no approved therapies. On the basis of preclinical activity of brigatinib (an inhibitor of multiple tyrosine kinases) in NF2-driven nonvestibular schwannoma and meningioma, data were needed on the use of brigatinib in patients with multiple types of progressive NF2-SWN tumors.

METHODS

In this phase 2 platform trial with a basket design, patients who were 12 years of age or older with NF2-SWN and progressive tumors were treated with oral brigatinib at a dose of 180 mg daily. A central review committee evaluated one target tumor and up to five nontarget tumors in each patient. The primary outcome was radiographic response in target tumors. Key secondary outcomes were safety, response rate in all tumors, hearing response, and patient-reported outcomes.

RESULTS

A total of 40 patients (median age, 26 years) with progressive target tumors (10 vestibular schwannomas, 8 nonvestibular schwannomas, 20 meningiomas, and 2 ependymomas) received treatment with brigatinib. After a median follow-up of 10.4 months, the percentage of tumors with a radiographic response was 10% (95% confidence interval [CI], 3 to 24) for target tumors and 23% (95% CI, 16 to 30) for all tumors; meningiomas and nonvestibular schwannomas had the greatest benefit. Annualized growth rates decreased for all tumor types during treatment. Hearing improvement occurred in 35% (95% CI, 20 to 53) of eligible ears. Exploratory analyses suggested a decrease in self-reported pain severity during treatment (-0.013 units per month; 95% CI, -0.002 to -0.029) on a scale from 0 (no pain) to 3 (severe pain). No grade 4 or 5 treatment-related adverse events were reported.

CONCLUSIONS

Brigatinib treatment resulted in radiographic responses in multiple tumor types and clinical benefit in a heavily pretreated cohort of patients with NF2-SWN. (Funded by the Children's Tumor Foundation and others; INTUITT-NF2 ClinicalTrials.gov number, NCT04374305.).

Для цитирования: Plotkin Scott R, Yohay Kaleb H, Nghiemphu Phioanh L, Dinh Christine T, Babovic-Vuksanovic Dusica, Merker Vanessa L, Bakker Annette, Fell Geoffrey, Trippa Lorenzo, Blakeley Jaishri O, INTUITT-NF2 Consortium. Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors.. The New England journal of medicine. 2024. DOI: 10.1056/nejmoa2400985.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.